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OBJECTIVE: To investigate the clinicopathological significance of podoplanin expression in the intratumoral stroma
and neoplastic cells of early stage uterine cervical cancer.
MATERIALS AND METHODS: A total of 143 patients with clinical stage I and IIA uterine cervical carcinomas
underwent surgery between 2000 and 2007. Clinicopathological data and slides associated with these cases were
retrospectively reviewed. Immunodetection of podoplanin expression in histologic sections of tissue microarray
blocks was performed using the monoclonal antibody D2-40.
RESULTS: Expression of podoplanin was detected in neoplastic cells in 31/143 (21.6%) cases, with 29/31 (93.5%) of
these cases diagnosed as squamous carcinoma. For all of the cases examined, the strongest signal for podoplanin
expression was observed at the proliferating edge of the tumor nests. The rate of positive podoplanin expression for
node-positive cases was lower than that of node-negative (18.9% vs. 22.6%, respectively). Furthermore, the rate of
positive podoplanin expression in fatal cases was 10.5% vs. 21.6%, respectively. In 27/143 (18.8%) cases, podoplanin
expression was detected in fibroblasts of the intratumoral stroma, and this expression did not correlate with patient
age, clinical stage, tumor size, histologic type, depth of infiltration, or vascular involvement. Moreover, expression
of podoplanin in intratumoral stroma fibroblasts was only negatively associated with nodal metastasis. A greater
number of fatal cases was observed among negative intratumoral stroma fibroblasts (15.5% vs. 3.7%, respectively),
although this difference was not significant.
CONCLUSIONS: These preliminary results suggest that podoplanin may have a role in host-tumor interactions and,
as a result, may represent a favorable prognostic factor for squamous cervical carcinomas.
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INTRODUCTION
Despite an increased emphasis on the use of intense
screening to diagnose cervical cancer in its early stages over
the past decade, higher rates of cervical cancer have recently
been observed among women.
1 In the United States, a
higher incidence of cervical cancer has also been associated
with African-American and Hispanic women.
2 In Brazil,
where uterine cervical cancer is the second most common
cancer diagnosed in women, the Brazilian National Cancer
Institute projects that approximately 18,430 new cases will
be diagnosed in 2010.
3 In the different geographical regions
of Brazil, the number of uterine cervical cancer cases ranges
from 12.93 to 31.18 per 100.000 women.
3 As with other types
of cancer, lymph node status is one of the most important
factors for patient prognosis and therapeutic strategy.
4,5
Therefore, there is a great need to define the mechanisms by
which tumor cells enter the lymphatic vessels to give rise to
lymph node metastases. Increasing evidence suggests that
the epithelial-mesenchymal transition (EMT) has a role in
the metastatic potential of neoplasias.
6 Although the
molecular mechanisms of this process have not been
completely elucidated, a number of signaling molecules
that may be involved have been identified, and all of these
have some type of association with loss of E-cadherin
function.
6 For cancers involving single cell migration and an
early dissemination of tumor cells, the EMT is considered to
be a particularly important event.
7 In contrast, the pattern of
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1279invasion by large cell sheets, often referred to as collective
cell migration, is a process that is less well understood.
Furthermore, unlike the EMT, these cell sheets maintain
expression of epithelial adhesion structures, yet still main-
tain the capacity to invade and destroy the host organ.
8,9
Podoplanin has been shown to mediate signaling that
facilitates collective cell migration and invasion both in vivo
and in vitro. These effects of podoplanin are in contrast with
those of E-cadherin.
8,9 Podoplanin has also been found to be
widely expressed in various types of specialized cells
throughout the body, including neoplastic cells associated
with uterine cervical cancer.
9,10 In addition, expression of
podoplanin has been observed in neoplastic cells of
squamous cell carcinomas localized to different areas of
the body, and to be associated with poor patient out-
comes.
10-12 However, in cases of stromal fibroblasts, the
significance of podoplanin expression remains controver-
sial.
13,14 Kawase et al. described the stromal expression of
podoplanin as an adverse prognostic factor in lung
carcinomas, while Yamanashi et al. found podoplanin
expression to be associated with a better prognosis in
patients with colorectal carcinomas.
13,14
In uterine cervical carcinoma, expression of podoplanin
by intratumoral stromal (ITS) cells has been cited, yet has
not been specifically investigated as a potential prognostic
factor.
10 Therefore, the goal of this study was to analyze the
association between stromal expression of podoplanin and
vascular invasion, nodal involvement, and prognosis of
uterine cervical cancers. In addition, the association between
neoplastic expression of podoplanin and patient prognosis
was examined. To our knowledge, this is the first study to
examine the significance of podoplanin expression by ITS
fibroblasts in cases of uterine cervical cancer.
MATERIALS AND METHODS
Institutional Certifications
This study was approved by the Department of Obstetrics
and Gynecology Scientific Committee of the Faculdade de
Medicina da Universidade de Sa ˜o Paulo, the Ethical
Committee for Research Projects of the Hospital das
Clinical da Faculdade de Medicina da Universidade de
Sa ˜o Paulo (Comissa ˜od eE ´tica para Ana ´lise de Pesquisa),
and the Ethical Committee for Research of the Instituto
Brasileiro de Controle do Cancer.
Patients and Pathological study
A cohort of 143 patients who underwent primary surgical
treatment at the Instituto Brasileiro de Controle do Cancer
(Sa ˜o Paulo, Brazil) between January 2000 and December
2007 for uterine cervical cancer were included in this study.
Only patients with at least one sample of lymph node tissue
available were included in the study. The clinicopathologi-
cal characteristics of these patients are listed in Tables 1 and
2. Between 4 and 51 lymph nodes were examined in each
case (median, 23) and in 7 cases, less than 10 lymph nodes
were examined per patient. Of these cases, 3 had positive
lymph nodes detected, while 4 cases were associated with
superficially invasive disease and had no signs of metas-
tasis. Patient demographics, clinical presentation, pathologic
characteristics, adjuvant therapy, recurrence and survival
outcome were compared for this cohort. Overall survival
was measured from the date of surgery to the date of death
from the disease, or the date the patient was last known to
be alive. The duration of follow-up ranged from 8-97 months
(median, 33), and all of the patients that completed less than
18 months of follow-up died as a result of the disease. All
slides were reviewed by two pathologists (BGLA, FMC),
and tumors were classified according to criteria of the
World Health Organization (WHO) Classification of
Tumors.
15 The presence of lymphatic space involvement
and depth of invasion were also evaluated for all cases. A
representative area of the tumor was selected for the
construction of tissue microarray blocks and immunohisto-
chemical study.
Construction of tissue microarray (TMA) blocks
Tumor areas were selected based on an analysis of slide
samples, whereby regions of tumor identified in the slides
were correspondingly marked in the matching paraffin
donor blocks. A cylinder, 2.0 mm in diameter, was punched
from each of the donor blocks and these were mounted into
paraffin blocks at 1 mm intervals using a precision
microarray instrument (Beecher Instruments, Silver Spring,
MD, USA). A grid system was established so that each core
would have a coordinate reference (i.e. x-axis, y-axis) for
sample identification. Blocks were sealed at 60˚C for 10 min
before 3 mm sections were prepared using standard
techniques. Sections were mounted on StarfrostH slides
(Knittel Glaser, Germany) and the first histologic sections
cut were stained with hematoxylin-eosin and examined to
ensure that the appropriate areas were included.
Table 1 - Clinicopathologic features of 143 cases of
uterine cervical cancer with respect to lymph node status
Lymph nodes p-value
Variable Positive n (%) Negative n (%)
Age, y 50.57 ¡ 15.42 50.28 ¡ 11.41 0.905
1
FIGO Stage
IB1 19 (13.3%) 64 (44.7%) 0.778
2
IB2 13 (9.1%) 31 (21.7%)
IIA 4 (2.8%) 12 (8.4%)
Tumor size 3.91 ¡ 1.74 cm 2.84 ¡ 1.60 cm 0.001
1
Depth of infiltration 1.04 ¡ 0.26 cm 0.73 ¡ 0.39 cm , 0.001
1
Histologic type
Squamous carcinoma 25 (17.5%) 76 (53.1%) 0.778
2
Adenocarcinoma 12 (8.4%) 30 (20.9%)
Histologic grade (n = 139)
1 4 (2.9%) 22 (15.8%) 0.264
2
2 26 (18.7%) 57 (41.0%)
3 7 (5.0%) 23 (16.5%)
Intravascular space involvement
Present 33 (23.1%) 35 (24.5%) , 0.001
2
Absent 4 (2.8%) 71 (49.6%)
Vaginal involvement
Present 10 (7.0%) 8 (5.6%) 0.020
2
Absent 28 (19.6%) 97 (67.8%)
Parametrial involvement
Present 10 (7.0%) 1 (0.7%) , 0.001
2
Absent 27 (18.9%) 105 (73.4%)
Podoplanin expression in ITS fibroblasts
Present 12 (8.4%) 15 (10.5%) 0.014
2
Absent 25 (17.5%) 91 (63.6%)
Podoplanin expression in cancer cells
Present 7 (4.9%) 24 (16.8%) 0.636
2
Absent 30 (20.9%) 82 (57.3%)
1Fisher’s analysis of variance
2Chi-square test
FIGO; International Federation of Gynecology and Obstetrics
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Additional histologic sections from tissue microarray
(TMA) blocks were quenched with 3% hydrogen peroxide
solution in phosphate-buffered saline (PBS; Sigma, St. Louis,
MO, USA) for 20 min to block endogenous peroxidase
activity. After several washes in PBS, sections were heated
in a microwave (Electrolux, 900W, Made in Brazil) for 15 min
in 0.01 M citrate buffer (pH 6.0), then cooled at RT for
20 min. Sections were then incubated with a monoclonal
antibody against human podoplanin (clone D2-40; 1400;
Dako, Carpinteria, CA, USA) overnight. Slides were washed
3 times with PBS then incubated with a novolink polymerH
detection system (Novocastra, Newcastle-upon-Tyne, UK),
with diaminobenzidine (DAB) as the chromogen.
Positive staining was associated with the cytoplasm of
endothelial cells of the lymphatic vessels, with the cyto-
plasm of epithelial cells, and with the cytoplasm of ITS cells.
For the purpose of this study, only the reactivity of
fibroblast-like stromal cells and neoplastic cells were
analyzed. When .10% of the ITS fibroblasts exhibited
unequivocal staining of at least moderate intensity, the
samples were recorded as positive. For the neoplastic cells,
when moderate or intense staining was observed in the
cytoplasm, independent of the number of stained cells
present, the sample was recorded to be positive and the
percentage of positive cells was recorded. Adjacent,
lymphatic endothelial cells exhibiting a normal phenotype
within each section served as positive internal controls.
False positives were evaluated based on an absence of
staining in all other non-endothelial cell types.
Statistical analyses
For comparison of age, tumor size and depth of
infiltration in relation to lymph node status and patient
survival, mean values were analyzed using Fisher’s analysis
of variance (ANOVA). The association between categorical
variables and lymph node status and survival were
evaluated using Pearson’s Chi-square test. These statistical
analyses were performed using Epi Info
TM, Version 3.5.1
software, (Atlanta, GA, USA).
16
RESULTS
Expression of podoplanin was identified in ITS cells in
27/143 (18.8%) cases. Of these cases, 22/27 (81.5%) were
diagnosed as squamous cell carcinomas and 5/27 (18.5%)
were diagnosed as adenocarcinomas (Fig. 1). Expression of
podoplanin was detected in the cytoplasm of neoplastic
cells in 31/143 (21.6%) cases and, of these, only 16/31
(11.2%) had a positively-stained population of more than
10%. For statistical purposes, any proportion of cells
exhibiting moderate or intense staining was recorded as a
positive result. Of the 5 cases diagnosed as adenocarcino-
mas, one was classified as an adenosquamous carcinoma,
and the positively stained cells were associated with the
squamous component. In all of the 31 cases examined, the
positively stained cells were observed to be localized at the
proliferating edge of the tumor nests (Fig. 2). Furthermore,
of the 31 cases associated with positive podoplanin
expression, 5 included positively stained ITS fibroblasts,
although this association was not significant.
Associations between the clinicalpathological factors
collected for each patient and lymph node status vs.
survival data for each patient are summarized in Tables 1
and 2, respectively. Among the classical prognostic factors,
there was no significant correlation between the presence of
positive lymph nodes and patient age, International
Federation of Gynecology and Obstetrics (FIGO is current
Table 2 - Associations between clinicopathologic features
in 143 cases of uterine cervical cancer and patient death
Variable Fatal Cases n (%) Alive n (%) p-value
Age, y 51.26 ¡ 15.85 50.22 ¡ 11.99 0.705
1
FIGO Stage
IB1 5 (3.5%) 78 (54.5%) 0.008
2
IB2 11 (7.7%) 33 (23.1%)
IIA 3 (2.1%) 13 (9.1%)
Tumor size 4.32 ¡ 2.12 cm 2.93 ¡ 1.55 cm 0.001
1





10 (7.0%) 90 (62.9%) 0.128
2
Adenocarcinoma 9 (6.3%) 34 (23.8%)
Histologic grade (n = 139)
1 1 (0.7%) 25 (18.0%) 0.928
2
2 15 (10.8%) 68 (48.9%)
3 3 (2.1%) 27 (19.4%)
Intravascular space involvement
Present 14 (9.7%) 54 (37.8%) 0.013
2
Absent 5 (3.5%) 70 (48.9%)
Vaginal involvement
Present 2 (1.4%) 16 (11.2%) 0.712
2
Absent 17 (11.9%) 108 (75.5%)
Parametrial involvement
Present 4 (2.8%) 7 (4.9%) 0.018
2
Absent 15 (10.4%) 117 (81.9%)
Podoplanin expression in ITS fibroblasts
Present 1 (0.7%) 26 (18.2%) 0.103
2
Absent 18 (12.6%) 98 (68.5%)
Podoplanin expression in cancer cells
Present 2 (1.4%) 29 (20.3%) 0.205
2
Absent 17 (11.9%) 95 (66.4%)
1Fisher’s analysis of variance
2Chi-square test
FIGO; International Federation of Gynecology and Obstetrics; ITS,
intratumoral stroma
Figure 1 - The intratumoral stroma (ITS) region of squamous
cell carcinoma. A representative histologic section of the ITS
region of a squamous cell carcinoma sample containing
fibroblast-like cells positive for podoplanin expression is shown.
(Immunohistochemistry, D2-40, original magnification, 4006).
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1281international denomination of the International Federation
of Gynecol. and Obstet., although the origin of the short
name comes from the French.) stage, histologic type, or
histologic grade (Table 1). However, tumor size (p = 0.001),
depth of infiltration (p , 0.001), intravascular space
involvement (p , 0.001), vaginal involvement (p = 0.020),
and parametrial involvement (p , 0.001) were associated
with positive lymph nodes (Table 1).
Regarding patient survival, age, histologic grade and
vaginal involvement were not found to be significant
prognostic factors. Adenocarcinomas were associated with
a greater frequency of fatal cases (20.9% vs. 9.9%); however,
this difference was not significant (p = 0.128, Table 2). In
addition, the mean depth of infiltration was found to be
greater for fatal cases, although this difference was also not
significant (Table 2). In contrast, patient death was
significantly associated with FIGO stage, tumor size,
vascular space involvement, and parametrial involvement
(Table 2).
Cases involving lymph node metastasis had a lower
proportion of cancer cells that expressed podoplanin (7/30,
18.9%) compared with cases without nodal involvement
(24/82, 22.6%). Fatal cases were also associated with a
reduced rate of podoplanin expression in the cancer cells
present (2/17, 10.5%) compared with surviving patients
(29/124, 23.4%). However, these differences were not
statistically significant.
Podoplanin expression in ITS fibroblasts was also found
to be negatively associated with lymph node metastasis (p
= 0.014). Although the proportion of fatal outcomes among
the positive cases was smaller than that of the negative cases
(3.7% vs. 15.5%), this difference was not statistically
significant.
DISCUSSION
A tumor’s microenvironment plays a significant role in
tumorigenesis, with the progression from local invasion to
distant metastasis events involving dynamic interactions
between tumor cells and their surrounding stromata.
Furthermore, the translocation of tumor cells depends on
cell-cell and cell-matrix interactions, degradation and
remodeling of the extracellular matrix, reorganization of
the cytoskeleton, and gain of migratory behavior.
17
Therefore, the role of the microenvironment in tumor
progression is a key factor in understanding cancer biology.
Recent data suggest that podoplanin may be involved in
cancer cell metastasis.
8,9 Podoplanin is a 38 kDa mucin-type
transmembrane glycoprotein that is specifically expressed
by lymphatic, but not blood vascular, endothelial cells. As
podoplanin appears to be present in smaller, rather than
larger, lymphatic vessels and blood vessels, it is considered
to be a reliable marker of lymphangiogenesis.
4 Podoplanin
has been hypothesized to have a role in the migration and
metastasis of cancer cells, that probably involves several
mechanisms. For example, Wicki et al. postulate that
podoplanin has the capacity to induce cancer cell invasion
by modulating not only collective cell migration, but also by
mediating single cell migration following the loss of E-
cadherin.
8,9
Recent studies have described podoplanin expression for
a subset of cancer cells, particularly squamous cell carcino-
mas.
10-12 In some of these studies, podoplanin expression
was associated with a poor patient outcome.
11,12 However,
the results of this study and of the work by Dumoff et al.,
identified a negative association between expression of
podoplanin in cervical cancer and vascular involvement,
and nodal metastasis.
10 These results emphasize that
podoplanin may have important biologic functions in
cancer dissemination, which remain to be characterized.
Furthermore, as demonstrated in this study and others,
expression of podoplanin is generally observed at the
invasion front of the tumors analyzed,
8,12 thereby support-
ing the hypothesis that cross-talk between neoplastic cells
and the stroma are the basis for mechanisms involving local
invasion and cellular migration to the lymphatic vessels.
Although recent studies have focused on the significance of
podoplanin expression in stromal fibroblasts,
13,14 these
results remain controversial. For example, while
Yamanashi et al. demonstrated that podoplanin expression
in stromal fibroblasts can be an indicator of good prognosis
in patients with advanced colorectal carcinoma,
13 other
studies have reported the expression of podoplanin to be
associated with a poor outcome.
12,14 In a study of uterine
cervical cancer by Dumoff et al., podoplanin reactivity was
more frequently observed in the ITS than in the normal
adjacent stroma. However, the authors did not investigate a
possible prognostic role.
10 In this study, a lower percentage
of cases expressing stromal podoplanin were observed
compared to the study by Dumoff et al., with 94 cases
(65.7%) being negative, and 22 (15.4%) cases containing no
more than 10% of the stromal cells exhibiting positive
expression of podoplanin. Furthermore, only 27 (18.9%)
cases exhibited strong expression of podoplanin in more
than 10% of the cells.
Most of the cases associated with positive expression of
podoplanin involved squamous cell carcinoma (81.5%),
which is consistent with previous reports.
9-12 In addition,
a significant association between stromal podoplanin
expression and lymph node metastasis was observed. For
survival, a fatal patient outcome was more frequently
associated with podoplanin-negative cases than with podo-
planin-positive cases, although this difference was not
statistically significant. These results suggest that podopla-
Figure 2 - Cytoplasmic expression of podoplanin in squamous cell
carcinoma. Detection of podoplanin expression in the cytoplasm
of neoplastic cells of a squamous cell carcinoma sample shows
that stronger expression of podoplanin is associated with the
front of invasion (Immunohistochemistry, D2-40, original magni-
fication, 1006)
Podoplanin expression in cervical cancer
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Moreover, the significance of these results to cases of
cervical cancer indicates that further investigation is
needed, particularly with a larger cohort of patients. A
phenotypic analysis of both stromal cells and cancer cells
would also provide further insight into the regulation of
podoplanin expression by stromal fibroblasts in relation to
interactions between stromal fibroblasts and the micro-
environment. It is anticipated that these mechanisms would
identify molecular targets for the treatment of uterine
cervical cancer in addition to other types of cancer.
CONCLUSIONS
Based on the small number of cases examined in this
study, our results only represent preliminary conclusions.
However, the observation that podoplanin was primarily
expressed in carcinomas with a squamous histologic type,
and the identification of a possible role for podoplanin in
mediating host-tumor interactions, suggests that podopla-
nin may act as a protective factor against invasion and
should be further investigated.
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